Longeveron Q2 net loss widens to $6.1M; cash $10.1M into Q4 2026; ELPIS II top-line Sept

Longeveron Inc.

2026-Q2 EPS reported -$0.38 revenue$685,000

Revenue flat at $0.3M; gross profit up 25% to ~$0.2M; G&A up 23% to $3.2M; R&D up 7% to $3.2M.
Net loss $6.1M vs $5.0M YoY; cash $10.1M expected to fund into Q4 2026; seeks additional financing.
ELPIS II Phase 2b top-line results for laromestrocel in HLHS expected September 2026; DMC no safety concerns.
Selected as XPRIZE Healthspan Finalist; receives $1.0M Milestone 2 Award; eligible for up to $81M Grand Prize.
Three new independent directors added to board; EMA SME status granted in June.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.